Anna is from Cambridge, England and recently finished her undergraduate degree, where she specialised in Biological Anthropology. She has an interest in medicine and enjoys writing. In her spare time she likes to cook, hike, and hang out with cats.

    A Marketing Application for the Gene Therapy LentiGlobin as a Treatment for Beta-Thalassemia is Being Reviewed in Europe
    <a href="https://pixabay.com/users/PublicDomainPictures/">PublicDomainPictures</a> / Pixabay

    A Marketing Application for the Gene Therapy LentiGlobin as a Treatment for Beta-Thalassemia is Being Reviewed in Europe

    According to a recent press release from Bluebird Bio, the European Medicines Agency has accepted and will review their marketing authorization application (MAA) for the investigational gene therapy LentiGlobin™ as…

    Continue Reading
    Plans for a Clinical Trial of Coversin in Patients With Thrombotic Microangiopathies Have Been Announced
    <a href="https://pixabay.com/users/mohamed_hassan/">mohamed_hassan</a> / Pixabay

    Plans for a Clinical Trial of Coversin in Patients With Thrombotic Microangiopathies Have Been Announced

    A drug called Coversin is being investigated as a potential treatment for four orphan diseases: bullous pemphigoid (BP), atypical keratoconjunctivitis (AKC), thrombotic microangiopathies, and paroxysmal nocturnal hemoglobinuria (PNH). Recently, new…

    Continue Reading
    Two Phase 2 Clinical Studies of a Drug for Rare Epilepsies Have Been Initiated
    <a href="https://pixabay.com/users/PublicDomainPictures/">PublicDomainPictures</a> / Pixabay

    Two Phase 2 Clinical Studies of a Drug for Rare Epilepsies Have Been Initiated

      Two Phase 2 clinical trials called ‘Elektra’ and ‘Arcade’ have been initiated. They will investigate the drug OV935/TAK-935 as a potential treatment for paediatric patients with rare epilepsies. For…

    Continue Reading
    Close Menu